Swiss HIV Cohort Study
13
4
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
7.7%
1 terminated/withdrawn out of 13 trials
85.7%
-0.8% vs industry average
23%
3 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
Role: collaborator
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Role: collaborator
Doxycycline PEP and 4CMenB as a Comprehensive Prevention Strategy in MSM and TGW at High Risk for Bacterial STIs Within the Swiss HIV Cohort Study
Role: collaborator
Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis
Role: collaborator
The SwissPrEPared Study
Role: collaborator
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
Role: collaborator
HIV - Monotherapy in Switzerland (MOST-ch)
Role: collaborator
Raltegravir in the Swiss HIV Cohort Study
Role: collaborator
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Role: collaborator
HIV Disclosure and Medication Adherence, a Pilot Study
Role: collaborator
Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
Role: collaborator
Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
Role: collaborator
Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring
Role: collaborator
All 13 trials loaded